Literature DB >> 16227547

How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales.

J C Hobart1, A Riazi, D L Lamping, R Fitzpatrick, A J Thompson.   

Abstract

OBJECTIVES: To compare the responsiveness of the Multiple Sclerosis Impact Scale (MSIS-29) with other self report scales in three multiple sclerosis (MS) samples using a range of methods. To estimate the impact on clinical trials of differing scale responsiveness.
METHODS: We studied three discrete MS samples: consecutive admissions for rehabilitation; consecutive admissions for steroid treatment of relapses; and a cohort with primary progressive MS (PPMS). All patients completed four scales at two time points: MSIS-29; Short Form 36 (SF-36); Functional Assessment of MS (FAMS); and General Health Questionnaire (GHQ-12). We determined: (1) the responsiveness of each scale in each sample (effect sizes): (2) the relative responsiveness of competing scales within each sample (relative efficiency): (3) the differential responsiveness of competing scales across the three samples (relative precision); and (4) the implications for clinical trials (samples size estimates scales to produce the same effect size).
RESULTS: We studied 245 people (64 rehabilitation; 77 steroids; 104 PPMS). The most responsive physical and psychological scales in both rehabilitation and steroids samples were the MSIS-29 physical scale and the GHQ-12. However, the relative ability of different scales to detect change in the two samples was variable. Differing responsiveness implied more than a twofold impact on sample size estimates.
CONCLUSIONS: The MSIS-29 was the most responsive physical and second most responsive psychological scale. Scale responsiveness differs notably within and across samples, which affects sample size calculations. Results of clinical trials are scale dependent.

Entities:  

Mesh:

Year:  2005        PMID: 16227547      PMCID: PMC1739386          DOI: 10.1136/jnnp.2005.064584

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales.

Authors:  A Riazi; J C Hobart; D L Lamping; R Fitzpatrick; A J Thompson
Journal:  Mult Scler       Date:  2003-08       Impact factor: 6.312

2.  Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach.

Authors:  G R Norman; P Stratford; G Regehr
Journal:  J Clin Epidemiol       Date:  1997-08       Impact factor: 6.437

3.  Validation of the functional assessment of multiple sclerosis quality of life instrument.

Authors:  D F Cella; K Dineen; B Arnason; A Reder; K A Webster; G karabatsos; C Chang; S Lloyd; J Steward; D Stefoski
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

4.  Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.

Authors:  J Hobart; N Kalkers; F Barkhof; B Uitdehaag; C Polman; A Thompson
Journal:  Mult Scler       Date:  2004-02       Impact factor: 6.312

5.  The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.

Authors:  C McGuigan; M Hutchinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

6.  Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).

Authors:  J C Hobart; A Riazi; D L Lamping; R Fitzpatrick; A J Thompson
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

7.  Evidence-based measurement: which disability scale for neurologic rehabilitation?

Authors:  J C Hobart; D L Lamping; J A Freeman; D W Langdon; D L McLellan; R J Greenwood; A J Thompson
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

8.  The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.

Authors:  J Hobart; D Lamping; R Fitzpatrick; A Riazi; A Thompson
Journal:  Brain       Date:  2001-05       Impact factor: 13.501

9.  Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples.

Authors:  A Riazi; J C Hobart; D L Lamping; R Fitzpatrick; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

10.  A neurological rehabilitation unit: audit of activity and outcome.

Authors:  J A Freeman; E D Playford; R S Nicholas; A J Thompson
Journal:  J R Coll Physicians Lond       Date:  1996 Jan-Feb
View more
  30 in total

Review 1.  The Spectrum of Functional Rating Scales in Neurology Clinical Trials.

Authors:  Pushpa Narayanaswami
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

2.  Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.

Authors:  Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

3.  Talking the talk on walking the walk: a 12-item generic walking scale suitable for neurological conditions?

Authors:  A Holland; R J O'Connor; A J Thompson; E D Playford; J C Hobart
Journal:  J Neurol       Date:  2006-08-21       Impact factor: 4.849

4.  Swedish natalizumab (Tysabri) multiple sclerosis surveillance study.

Authors:  Fredrik Piehl; C Holmén; J Hillert; T Olsson
Journal:  Neurol Sci       Date:  2011-01       Impact factor: 3.307

5.  The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical).

Authors:  Lisa Costelloe; Killian O'Rourke; Hugh Kearney; Christopher McGuigan; Lisa Gribbin; Marguerite Duggan; Leslie Daly; Niall Tubridy; Michael Hutchinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-01       Impact factor: 10.154

6.  The 27-Item Multiple Sclerosis Quality of Life Questionnaire: A New Brief Measure Including Treatment Burden and Work Life.

Authors:  Helen Beckmann; Christoph Heesen; Matthias Augustin; Christine Blome
Journal:  Int J MS Care       Date:  2021-12-07

7.  Responsiveness of walking-based outcome measures after multiple sclerosis relapses following steroid pulses.

Authors:  Petar Filipović Grčić; Meri Matijaca; Ivo Lušić; Vesna Čapkun
Journal:  Med Sci Monit       Date:  2011-12

8.  Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29.

Authors:  Melina Ramp; Fary Khan; Rose Anne Misajon; Julie F Pallant
Journal:  Health Qual Life Outcomes       Date:  2009-06-22       Impact factor: 3.186

9.  The physical and psychological impact of multiple sclerosis using the MSIS-29 via the web portal of the UK MS Register.

Authors:  Kerina H Jones; David V Ford; Philip A Jones; Ann John; Rodden M Middleton; Hazel Lockhart-Jones; Jeffrey Peng; Lisa A Osborne; J Gareth Noble
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  Protocol for the saMS trial (supportive adjustment for multiple sclerosis): a randomized controlled trial comparing cognitive behavioral therapy to supportive listening for adjustment to multiple sclerosis.

Authors:  Rona Moss-Morris; Laura Dennison; Lucy Yardley; Sabine Landau; Suzanne Roche; Paul McCrone; Trudie Chalder
Journal:  BMC Neurol       Date:  2009-08-23       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.